Platelet Pathology in Patients with Chronic Diffuse Liver Diseases with Viral Etiology
DOI:
https://doi.org/10.61841/aq8yez87Keywords:
Thrombocytopenias, Hemorrhagic Syndrome, Liver Cirrhosis, Chronic Viral Hepatitis, Mean Platelet Volume, Platelet Anisocytosis, Plateletcrit, Bone MarrowAbstract
Objective of the research: Study of platelet hemostasis disorders in patients with chronic hepatitis and liver cirrhosis of viral etiology.
Materials and methods: The study included 142 patients with chronic diffuse liver diseases, including 80 patients with liver cirrhosis of viral etiology and 62 patients with chronic viral hepatitis of moderate activity.
Research results: Hemorrhagic syndrome was expressed in a group of patients with liver cirrhosis of HBV and HBV+HDV etiology in 63.3% and 70.0%, respectively. Hematological and cytomorphological studies of platelets in patients with liver cirrhosis and chronic hepatitis of viral etiology showed significant abnormalities in the amount of blood cells and platelet morphology in liver cirrhosis and minor changes in chronic hepatitis. Liver cirrhosis of viral etiology was accompanied by significant changes in thrombocytopoiesis in the red bone marrow with severe depression of the megakaryocytic lineage and significant abnormal platelet production in the bone marrow.
Conclusions: In LC and chronic hepatitis of viral etiology, morphological characteristics of platelets and production of platelets in bone marrow are disturbed, which is the cause of hemorrhagic syndrome in 34.3-11.6% of LC patients in the stage of decompensation and in 9.6-3.1% of patients with chronic viral hepatitis.
Downloads
References
[1] Clevenger B., Susan V. Transfusion and coagulation management in liver transplantation // World Journal of Gastroenterology. – 2014. – Vol. 20. – P. 6146–6158.
[2] Dahal, S. et al. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis 9, e2017019, https://doi.org/10.4084/MJHID.2017.019 (2017).
[3] Gangireddy, V.G., Kanneganti, P.C., Sridhar, S., Talla, S. & Coleman, T. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol 28, 558–564 (2014).
[4] Global hepatitis report, 2017 (WHO)
[5] Hayashi, H., Beppu, T., Shirabe, K., Maehara, Y. & Baba, H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol 20, 2595–2605, (2014).
[6] Hartmann M., Cynthia S., Fuat H. Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment // World Journal of Gastroenterology. – 2016. – Vol. 22 (4), – P. 1541–1550.
[7] Huang, H.S., Sun, D.S., Lien, T.S. & Chang, H.H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood 116, 5002–5009 (2010).
[8] Intagliata, N.M. et al. Concepts and Controversies in Hemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 118, 1491–1506, 2018.
[9] Lambert, M.P. & Gernsheimer, T.B. Clinical updates in adult immune thrombocytopenia. Blood 129, 2829–2835, 2017.
[10] Lisman T., Caldwell S.H. et al. Coagulation in Liver Disease Study Group. Hemostasis and thrombosis in patients with liver disease: the ups and downs // J. Hepatol. – 2010. – Vol. 53(2), – P. 362–371.
[11] Maan, R., de Knegt, R.J. & Veldt, B.J. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 75, 1981–1992 (2015).
[12] Pluta A., Gutkowski K., Hartleb M. Coagulopathy in liver diseases //Аdvanced in Medical Sciences. –2010. – Vol. 55 (1), –P. 16–21.
[13] Tripodi A., D'Ambrosio R., Padovan L., Tosetti G., Aghemo A. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus-related cirrhosis // Liver Int. – 2017. – Vol. 37(9), – P. 1295–1303.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.